Brief: Denali Therapeutics Q4 Operating Expenses USD 137.365 Million
26/02/2026 21:01
Feb 26 (Reuters) - Denali Therapeutics Q4 pretax profit USD -128.447 million. Q4 basic EPS USD -0.73 Q4 operating income USD -137.365 million Q4 net income USD -128.549 million
Recent news on Denali Therapeutics
See all newsDenali Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Denali Therapeutics Q2 net loss widens as AVLAYAH launch costs rise
Biogen's Alzheimer's drug lowers toxic protein, but results were mixed
U.S. STOCKS ON THE MOVE-Sweetgreen, Dell Technologies, Peloton Interactive
U.S. STOCKS ON THE MOVE-IMAX, Novo Nordisk, PC makers